Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Medical Minute on Key Decisions in HIV Care: Considering Rapid ART in a Patient with Opioid Use Disorder

In this case example, learn the importance of initiation of treatment for OUD along with ART initiation
Jason Halperin, MD, MPH
Released: September 10, 2021

Information on this Educational Activity

Faculty

Jason Halperin, MD, MPH

Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana

Jason Halperin, MD, MPH, has no relevant conflict of interest to report.

Program Medium

This program has been made available online.

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Slides on HIV ART management in complex clinical situations, including extensive previous treatment, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: January 11, 2023

Slides on HIV ART management in complex clinical situations, including extensive previous treatment, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: January 10, 2023

Dr Christine Katlama discusses minimizing ART exposure with dual-therapy and intermittent dosing strategies, from Clinical Care Options (CCO)

person default Christine Katlama, MD Released: January 4, 2023
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings